These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17987230)

  • 21. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tigecycline: CMI 50/90 towards 1766 Gram-negative bacilli (3rd generation cephalosporins resistant enterobacteriaceae), Acinetobacter baumannii and Bacteroides fragilis group, University Hospital - Montpellier, 2008-2011].
    Froment Gomis P; Jean-Pierre H; Rousseau-Didelot MN; Compan B; Michon AL; Godreuil S
    Pathol Biol (Paris); 2013 Dec; 61(6):282-5. PubMed ID: 23478078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
    Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
    Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.
    Draghi DC; Tench S; Dowzicky MJ; Sahm DF
    Chemotherapy; 2008; 54(2):91-100. PubMed ID: 18303257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
    Casal M; Rodríguez F; Johnson B; Garduno E; Tubau F; de Lejarazu RO; Tenorio A; Giménez MJ; Bartolomé R; Garcia-Rey C; Aguilar L; García-Escribano N
    J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
    Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro activity of tigecycline against multiple resistant Acinetobacter baumannii and carbapenem resistant Klebsiella pneumoniae isolates].
    Arikan Akan O; Uysal S
    Mikrobiyol Bul; 2008 Apr; 42(2):209-15. PubMed ID: 18697418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
    Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
    Rajenderan S; Balaji V; Anandan S; Sahni RD; Tansarli GS; Falagas ME
    PLoS One; 2014; 9(7):e103253. PubMed ID: 25068396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain].
    García-Rodríguez JA;
    Rev Esp Quimioter; 2009 Jun; 22(2):76-82. PubMed ID: 19554486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F; Dowzicky MJ
    J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F; Arslan H; Azap OK; Senger SS; Başaran O; Karaman SO; Haberal M
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tigecycline susceptibility in multidrug resistant Acinetobacter isolates from Turkey.
    Yilmaz FF; Taşli H; Gül-Yurtsever S; Büyük A; Hoşgör-Limoncu M
    Pol J Microbiol; 2013; 62(3):295-8. PubMed ID: 24459835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.